Nutrition reviews · 2025
Role of Vitamin D Supplementation in Chronic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martinekova Petrana, Obeidat Mahmoud, Topala Mihaela, Váncsa Szilárd, Veres Dániel Sándor, Zolcsák Ádám, Pál Miheller, Földvári-Nagy László, Banovcin Peter, Erőss Bálint, Hegyi Péter, Hagymasi Krisztina
Аннотация
CONTEXT: Vitamin D deficiency is highly prevalent in chronic liver disease. Although international societies recommend vitamin D supplementation in cases of proven deficiency, the impact of vitamin D on chronic liver disease remains uncertain.
OBJECTIVE: Our aim was to evaluate the effects of vitamin D supplementation in patients with chronic liver disease by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs).
DATA SOURCES: We systematically searched PubMed, EMBASE and the Cochrane Library on July 2, 2024.
DATA EXTRACTION: Our primary outcomes involved survival, controlled attenuation parameter (CAP), liver stiffness measurement (LSM), and effects on changes in liver enzymes. Secondary outcomes included lipid profile and homeostasis model assessment of insulin resistance (HOMA-IR), among others. The pooled risk ratio (RR), mean difference (MD), and corresponding 95% CIs were calculated using the random-effects model.
DATA ANALYSIS: Forty-six RCTs were included, comprising 4084 patients. When we compared the vitamin D group with the control, the RR for overall survival was 1.14 (95% CI, 0.85-1.54; 4 RCTs) at 6 months and 0.99 (95% CI, 0.83-1.17; 4 RCTs) at the 12-month follow-up. Vitamin D supplementation did not result in a lower CAP (MD, -23.50 dB/m; 95% CI, -81.72 to 34.72; 3 RCTs) and LSM (MD, -0.65 kPa; 95% CI, -1.98 to 0.68; 3 RCTs). A significant reduction in HOMA-IR was observed in the vitamin D group (MD, -0.31; 95% CI, -0.62 to -0.01; 15 RCTs). Alanine aminotransferase (ALT) (MD, -4.98 IU/L; 95% CI, -8.28 to -1.68; 24 RCTs), aspartate aminotransferase (AST) (MD, -3.33 IU/L; 95% CI, -6.25 to -0.40; 23 RCTs), gamma-glutamyl transferase (GGT) (MD, -5.14 IU/L; -6.40; -3.88; 11 RCTs), triglycerides (MD, -7.59 mg/dL; 95% CI, -15.09 to -0.81), and insulin (MD -0.79 μIU/L; 95% CI, -1.36 to -0.21) were significantly reduced in the patients with vitamin D supplementation.
CONCLUSION: Our results showed significantly reduced ALT, AST, GGT, triglycerides, insulin, and HOMA-IR in the vitamin D-supplemented group; however, the effect was modest. In addition, there were no differences in survival, CAP, or LSM. Further RCTs with adequate power are warranted to clarify the results.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration No. CRD42022370312.
OBJECTIVE: Our aim was to evaluate the effects of vitamin D supplementation in patients with chronic liver disease by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs).
DATA SOURCES: We systematically searched PubMed, EMBASE and the Cochrane Library on July 2, 2024.
DATA EXTRACTION: Our primary outcomes involved survival, controlled attenuation parameter (CAP), liver stiffness measurement (LSM), and effects on changes in liver enzymes. Secondary outcomes included lipid profile and homeostasis model assessment of insulin resistance (HOMA-IR), among others. The pooled risk ratio (RR), mean difference (MD), and corresponding 95% CIs were calculated using the random-effects model.
DATA ANALYSIS: Forty-six RCTs were included, comprising 4084 patients. When we compared the vitamin D group with the control, the RR for overall survival was 1.14 (95% CI, 0.85-1.54; 4 RCTs) at 6 months and 0.99 (95% CI, 0.83-1.17; 4 RCTs) at the 12-month follow-up. Vitamin D supplementation did not result in a lower CAP (MD, -23.50 dB/m; 95% CI, -81.72 to 34.72; 3 RCTs) and LSM (MD, -0.65 kPa; 95% CI, -1.98 to 0.68; 3 RCTs). A significant reduction in HOMA-IR was observed in the vitamin D group (MD, -0.31; 95% CI, -0.62 to -0.01; 15 RCTs). Alanine aminotransferase (ALT) (MD, -4.98 IU/L; 95% CI, -8.28 to -1.68; 24 RCTs), aspartate aminotransferase (AST) (MD, -3.33 IU/L; 95% CI, -6.25 to -0.40; 23 RCTs), gamma-glutamyl transferase (GGT) (MD, -5.14 IU/L; -6.40; -3.88; 11 RCTs), triglycerides (MD, -7.59 mg/dL; 95% CI, -15.09 to -0.81), and insulin (MD -0.79 μIU/L; 95% CI, -1.36 to -0.21) were significantly reduced in the patients with vitamin D supplementation.
CONCLUSION: Our results showed significantly reduced ALT, AST, GGT, triglycerides, insulin, and HOMA-IR in the vitamin D-supplemented group; however, the effect was modest. In addition, there were no differences in survival, CAP, or LSM. Further RCTs with adequate power are warranted to clarify the results.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration No. CRD42022370312.